MOY is required to meet guidance. Unfortunate that they couldn't meet the first half guidancefigure but as they said it is really a timing issue and delays in development.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025